Dr Gary Acton |
Biography:
Gary Acton is a medical oncologist based in London. He became a
doctor by accident, having originally gone to university to do
something completely different. However, after inadvertently ending
up at Oxford and London medical schools he decided to give it a go
and found to his surprise (and everyone else’s) that he was actually
quite good.
After a long period wandering the wards of London hospitals, he
eventually left clinical practice, as his hypochondria was getting
worse and worse. Following a spell studying mediaeval theology
(don’t try this at home) he moved into research and development and
has been working on new anti-cancer drugs ever since.
He is currently Senior Medical Advisor to Cancer Research UK and is
also medical advisor to the UK government’s cancer cellular therapy
initiative. Additionally he provides strategic cancer drug
development consultancy to a number of US and European biotechnology
companies and academic institutions. |
|
|
Professor Mark Caulfield |
Biography:
Mark Caulfield graduated in Medicine in 1984 from the London
Hospital Medical College and trained in Clinical Pharmacology at St
Bartholomew’s Hospital where he developed a research programme in
molecular genetics of hypertension which has discovered over 1000
gene loci for blood pressure.
He was appointed Director of the William Harvey Research Institute
in 2002 and was elected a Fellow of the Academy of Medical Sciences
in 2008. Between 2010 and 2015 he co-led the merger of three
hospitals in North London to create the new £400 million Barts Heart
Centre which provides 80,000 cardiovascular patient episodes.
He has won the Lily Prize of the British Pharmacology Society, the
Bjorn Folkow Award of the European Society of Hypertension 2016 and
the Franz Volhard Award of the International Society of Hypertension
in 2018.
In 2013 he became an NIHR Senior Investigator and was appointed as
the Chief Scientist for Genomics England (100,000 Genomes Project).
He was appointed Interim Chief Executive Officer for Genomics
England from January to September 2019. Sir Mark was awarded a
Knighthood in the June 2019 Queen’s Birthday Honours List for
services to the 100,000 Genomes Project. |
|
|
Dr David J Collier |
Biography:
David trained in medicine at Barts, won one of the first Wellcome
Trust Prize Studentships to do a PhD in physiology during his
medical degree, led the research team on the British Mount Everest
Medicial Expedition in 1994 and has worked on clinical trials since
1997. He is Clinical Director - William Harvey Clinical Research
Centre, Clinical and Public and Patient Involvement/Engagement Lead
- Barts Cardiovascular Clinical Trials Unit, Public and Patient
Involvement & Engagement Strategy Lead - Barts Biomedical Research
Centre and Interim Director - Barts CTU (UKCRC registered Clinical
Trials Unit). His Clinical Research Centre has recruited large
numbers of patients (such as 1157 patients for ASCOT) for 22 years
and working with those patients they have influenced the development
of many new therapies and also patient collaborations such as
Chiaroscuro- marking the 70th Anniversary of the Nuremberg Trials. |
|
|
Gary Cook |
Biography:
Gary Cook is Deputy Director in the Office for Life Sciences (OLS)
responsible for three areas of core Government policy. Firstly, the
strategy, vision and policy for genomics, the use of a person’s DNA
to help prevent or cure illness. Secondly, data policy for OLS,
improving the health of the nation through better use of NHS data by
partners developing innovative treatments. Thirdly, specific
responsibilities concerning resilience in the supply chain, ensuring
continuity of supply into the UK and appropriate risk mitigation.
Gary has nearly eight years’ experience in the Civil Service across
five Government Departments, and five years’ experience in the
private sector working in digital and data.
Gary has an MSc in Public Policy from LSE, an MSc in Information
Technology for e-Commerce from the University of Sussex and a BSc in
Information Systems from the University of Newcastle-upon-Tyne. |
|
|
Matt Cooper |
Biography:
The National Institute for Health Research Clinical Research Network
is the research delivery arm of the NHS. It invests some £300m each
year into an infrastructure of clinical research professionals
across England, to support rapid study set-up and patient
recruitment into clinical research studies (academic and
commercial). The Network has demonstrated year-on-year improvements
in patient recruitment numbers and delivery times for commercial
studies.
In 2018/19 the NIHR CRN supported the recruitment of 46,064 patients
into commercial contract clinical trials from1523 open and
recruiting studies. Demonstrating efficient and effective set up and
delivery of clinical trials at scale in our single healthcare
provider - the National Healthcare Service.
Matt has been involved in the Network since 2006 and an Executive
Director at the Clinical Research Network Coordinating Centre since
2014 and brings a wealth of experience to the post. Matt plays a key
role in promoting the UK as a prime destination of choice for
clinical research at the frontier of innovation and technology.
In previous roles Matt worked in the Clinical Research Group of
AstraZeneca UK for a number of years and in the NHS coordinating
clinical trials. |
|
|
Stuart Evans |
Biography:
Stuart Evans is a Pharmacology graduate from the University of Bath
with over 10 years of experience in Clinical Research. He has worked
at both large and small CROs before joining AMO Pharma, a small,
virtual biopharmaceutical company.
His experience includes pharmacovigilance, quality systems,
monitoring and study management in various therapeutic areas; now
focusing on paediatric neurodevelopmental rare diseases as Associate
Director of Clinical Development at AMO Pharma. |
|
|
Sarah Fryer |
Biography:
Sarah Fryer, founder of the independent consultancy QRC Consultants,
has over 30 years’ experience in the pharmaceutical industry,
primarily in the management of clinical research programmes, GCP QA
auditing and Quality Systems Management and with a particular
interest in the development of advanced therapies.
A graduate from Surrey University with an MSc in Toxicology, Sarah
moved from pre-clinical research into clinical drug development
working in both small company and CRO environments.
As Managing Director for the UK office of the international CRO
Harrison Clinical Research, she facilitated the attainment of ISO
certification for the company. In 2003, she was co-founder of
Gregory Fryer Associates.
Sarah is now Director of QRCC, based in St Ives, Cambridgeshire,
leading a team of QA, regulatory and clinical research consultants. |
|
|
Alex Gage |
Biography:
Alex graduated from the University of Nottingham with a BSc (Hons)
and has over 20 years’ experience within the pharmaceutical
industry, working primarily within clinical operations managing
clinical trials and project teams both within the UK and globally.
Alex has held numerous positions at a large pharmaceutical company,
worked as an independent consultant and for a UK-based Contract
Research Organisation. Alex has experience of a wide range of
therapeutic areas within clinical research across different phases
of development. |
|
|
Dr Matthew Hallsworth |
Biography:
Dr Matthew Hallsworth is
Head of External Relations for the NIHR Office for Clinical Research
Infrastructure (NOCRI). He leads on external stakeholder relations,
including engagement with the bio-pharma industry.
NOCRI works with companies to support collaboration with the expert
investigators and research facilities funded by the UK Department of
Health, from early-phase translational medicine through to
later-phase clinical trials.
Prior to NOCRI Matthew was Head of Communications at the UK Clinical
Research Collaboration – a partnership of government, charities,
industry, the NHS, academia, regulators and patients focused on
improving the clinical research environment in the UK.
Matthew has had Research Management roles at the medical charity
Asthma UK and for the Department of Health’s National R&D Programme.
During his earlier career Matthew was a Research Fellow in
Respiratory Medicine at Guy’s & St Thomas’ Hospitals, London, where
he completed his PhD on inflammatory mechanisms in asthma and
allergic disease. |
|
|
Dr Ali Hansford |
Biography:
Dr Hansford is the Head of Regulatory Strategy at the Association of
the British Pharmaceutical Industry (ABPI), a role which covers the
policy areas of clinical research, regulation of trials and
medicines, licensing and access schemes. Prior to this, Dr Hansford
was the Head of Science Policy at the ABPI.
Before moving to the ABPI, Dr Hansford worked in the Policy &
Knowledge team at Prostate Cancer UK. Dr Hansford holds a PhD in the
immunology of asthma and allergy from King’s College London and an
M.Sci in Pharmacology from the University of Bristol. |
|
|
Steve Hoare |
Biography:
Steve trained as an analytical chemist and has experienced the
medicines lifecycle as a QC or QA Lead from early discovery through
to marketing approval, manufacture and distribution, driving
compliance in pretty much every “x” in GxP. Steve’s team at ABPI
work with members’ expert communities to develop and advocate Brexit
and Brexit-agnostic policies that increase the attractiveness of the
UK for investment in R&D and Manufacturing. |
|
|
Paul Bowers Isaacson |
Biography:
Paul is a professional educator working in the areas of curriculum
development and assessment nationally, for example developing the
Extended Project Qualification for sixth form students. He is also
an experienced facilitator and offers facilitation and presentation
training for various voluntary groups. Some years ago Paul joined a
clinical trial overseen at the William Harvey Clinical Research
Centre. Paul’s interest in clinical trials had started a few years
earlier in the context of developing A Level Science and Society
with the Nuffield Curriculum Centre. He has since worked with David
Collier at William Harvey to create TrialsConnect as a voluntary
organisation of patients inspired by the power of ‘Patient Story’. |
|
|
Professor Atholl Johnston |
Biography:
Professor Atholl
Johnston is Professor of Clinical Pharmacology at Barts and The
London School of Medicine and Dentistry, Queen Mary’s, University of
London, visiting Professor of Forensic Pharmacology and Toxicology
at St George’s, University of London, and the Director of the
laboratory of Analytical Services International Ltd. He is a Fellow
of the British Pharmacological Society, the Royal College of
Pathologists, the Royal Society of Medicine, the Faculty of
Pharmaceutical Medicine, and the Royal Statistical Society. He is a
Chartered Scientist, a European Registered Toxicologist, and a state
registered Clinical Scientist.
Professor Johnston has more than 35 years’ experience in the
measurement of drugs as a guide to therapy. He has published over
two hundred and sixty articles in peer-reviewed journals.
Professor Johnston was a Founder member of CCRA and is currently its
President. |
|
|
Ian King |
Biography:
Ian is the Deputy Director of the EU & International Policy team at
MHRA, heading up the Agency’s EU Exit work, having previously been
responsible for leading the Agency’s Brexit No Deal readiness. Prior
to this Ian worked on EU carbon pricing negotiations at BEIS/DECC
and was part of the DECC strategy team. He has a PhD in solid-state
analytical chemistry, and worked as a research scientist in the
pharmaceutical industry at the start of his career.
|
|
|
Emma Lewis |
Biography:
Emma graduated with a BSc (Hons) in Applied Biology from Brunel University before joining the pharmaceutical Industry as a CRA in 1995.
Since then Emma has had a diverse career within large pharma and both large and small CROs.
Currently Emma is a Senior Director of Clinical Operations with PRA Health Sciences responsible for the recruitment, training and development of clinical operations staff and the delivery of clinical studies across multiple countries including the UK.
Emma represents Clinical Operations on the PRA Health Sciences Brexit task force.
|
|
|
Emma Lowe |
Biography:
Emma works within the
Science, Research and Evidence Directorate at the Department of
Health and Social Care, leading on research policy for industry
relations and growth. Her role includes supporting the
implementation of the Life Sciences Industrial Strategy, enhancing
the NIHR’s offer for Industry, and other areas of policy which
contribute to making the UK the destination of choice for life
sciences research. Working with the Office for Life Sciences, Emma
led the Clinical Research workstream of the Life Sciences Sector
Deal 2.
Emma has an MSc in People and Organisational Development from the
Roffey Park Institute, has held a variety of roles within the NHS
and previously led the design and delivery of learning and workforce
development programmes in the NIHR Clinical Research Network,
including the NIHR’s Good Clinical Practice (GCP) programme. |
|
|
Liz Madichie |
Biography:
Liz Madichie is a senior
bio-pharmaceutical executive passionate about influencing change to
improve health equality worldwide and enable patients and consumers
live longer healthier lives. She has extensive experience in global
regulatory, pharmacovigilance and product development strategies,
both in the biopharmaceutical and CRO industry.
As an active industry advocate, and TOPRA Board member, Liz
proactively pursues opportunities to advance the regulatory
paradigm. She is a recognised thought leader, delivering several
presentations, publications and engages in various industry forum.
An experienced leader of global regulatory functions, Liz most
recently led the PPD global regulatory affairs function providing
consultancy and operational delivery across all elements of the
product development and commercialization continuum.
Liz holds a doctorate in analytical chemistry from the University of
Hull and previously held leadership roles with Taro Pharmaceuticals,
Élan Pharmaceuticals and GlaxoSmithKline. |
|
|
Dr Janet Messer |
Biography:
Janet Messer is Director
of Approvals Service at the Health Research Authority. She is
responsible for the Research Ethics, Confidentiality Advice,
Assessment and Assurance services, alongside the supporting
guidance, advice and learning functions. Her team works
collaboratively with a wide range of partner organisations to fulfil
the HRA’s aims to make it easier to do good quality ethical research
in the UK. Prior to working at the HRA she was Head of Research
Management and Governance at the NIHR Clinical Research Network. She
has a PhD in biochemistry from University of Cambridge and a Masters
in Medical Law, along with many years’ experience of clinical
research in the pharmaceutical industry and working with NHS R&D. |
|
|
Dr Martin O’Kane |
Biography:
Dr Martin O'Kane
MRPharmS is Head of the Clinical Trials Unit at the Medicines and
Healthcare products Regulatory Agency (MHRA). He studied pharmacy at
University of Aston and after completing a PhD and post-doctorate
research project at the University of Glasgow, moved to Japan to
work within the pharmaceutical industry. He joined the MHRA in 2005
as a Pharmacopoeial Scientist within the British Pharmacopoeia and
moved to the MHRA Clinical Trials Unit as a Pharmaceutical Assessor
in 2007. He became Head of the Clinical Trials Unit in November 2015
and is actively involved in European and UK projects to prepare for
implementation of the new clinical trials Regulations as well as the
UKs exit from the EU. |
|
|
Sarah Testori |
Biography:
Sarah Testori works within the Science, Research and Evidence
Directorate at the Department of Health and Social Care and is
responsible for Brexit policy in relation to health research and
clinical trials. Prior to that she held science and healthcare
policy roles at Cancer Research UK and the Human Fertilisation and
Embryology Authority. Sarah also has a PhD in Molecular Genetics. |
|
|
Dr Lincoln Tsang |
Biography:
Dr Lincoln Tsang is a partner of Arnold & Porter Kaye Scholer LLP’s
Global Life Sciences Practice. His legal practice is concentrated on
regulatory, compliance, enforcement, litigation and legislative
public policy matters relating to the life sciences sector. He has
served as a Commissioner of the British Pharmacopoeia Commission; a
non-executive board member of the National Institute for Biological
Standards and Control (now part of the MHRA); and as a non-executive
member of the Regulatory Oversight Committee of the Health
Protection Agency. He spent nearly 13 years in the UK regulatory
agency and was latterly head of biologicals and biotechnology. He
has served as an advisor to the European Medicines Agency, the
European Commission and the WHO concerning international trade of
medicines. He was appointed recently by the Council of Europe as a
special advisor on the development of the MediCrime Convention to
combat counterfeit healthcare products. He was a member of the UK
Ministerial Industry Strategic Group for pharmaceuticals. |
|